Tempest Therapeutics Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Public

  • Employees
  • 4

Employees

  • Stock Symbol
  • TPST

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $0.29
  • (As of Friday Closing)

Tempest Therapeutics General Information

Description

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.

Contact Information

Formerly Known As
Inception 2, Next Beta, Millendo Therapeutics, OvaScience
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 2000 Sierra Point Parkway
  • Suite 400
  • Brisbane, CA 94005
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 2000 Sierra Point Parkway
  • Suite 400
  • Brisbane, CA 94005
  • United States

Tempest Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Tempest Therapeutics Stock Performance

As of 20-Nov-2026, Tempest Therapeutics’s stock price is $0.29. Its current market cap is $5.74M with 20M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.29 $0.31 $0.28 - $4.22 $5.74M 20M 2.52M -$3.16

Tempest Therapeutics Financials Summary

As of 30-Sep-2026, Tempest Therapeutics has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 20,872 15,032 32,041 94,577
Revenue 0 0 0 0
EBITDA (39,629) (26,309) (41,637) (28,776)
Net Income (40,590) (26,262) (41,843) (29,491)
Total Assets 8,761 16,931 41,488 51,603
Total Debt 7,258 8,141 15,365 20,661
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Tempest Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Tempest Therapeutics‘s full profile, request access.

Request a free trial

Tempest Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Tempest Therapeutics‘s full profile, request access.

Request a free trial

Tempest Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to trea
Drug Discovery
Brisbane, CA
4 As of 2026

Wilmington, DE
 

Plymouth Meeting, PA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Tempest Therapeutics Competitors (4)

One of Tempest Therapeutics’s 4 competitors is Ayala Pharmaceuticals, a Corporation company based in Wilmington, DE.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ayala Pharmaceuticals Corporation Wilmington, DE
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
Aura Biosciences Formerly VC-backed Boston, MA
AVEO Oncology Formerly VC-backed Boston, MA
To view Tempest Therapeutics’s complete competitors history, request access »

Tempest Therapeutics Patents

Tempest Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026198803-A1 Formulations of triazolone compounds and uses thereof Pending 20-Mar-2025
WO-2026198779-A1 Methods of making a ppar alpha antagonist Pending 20-Mar-2025
WO-2025235527-A1 Crystalline forms of a ppar alpha antagonist Pending 08-May-2024
WO-2024102968-A1 Uses of ep2/ep4 antagonist compounds for treating familial adenomatous polyposis (fap) Inactive 10-Nov-2022
WO-2024102620-A2 Triazolone compounds and uses thereof Inactive 09-Nov-2022 A61K31/4196
To view Tempest Therapeutics’s complete patent history, request access »

Tempest Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Tempest Therapeutics Investments & Acquisitions (2)

Tempest Therapeutics’s most recent deal was a Corporate Asset Purchase with Factor Bioscience (Certain Dual-Targeting Chimeric Antigen Receptor (CAR)-T Programs). The deal was made on 04-Feb-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Factor Bioscience (Certain Dual-Targeting Chimeric Antigen Receptor (CAR)-T Programs) 04-Feb-2026 Corporate Asset Purchase Drug Discovery
Millendo Therapeutics 25-Jun-2021 Merger/Acquisition Biotechnology
To view Tempest Therapeutics’s complete investments and acquisitions history, request access »

Tempest Therapeutics ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view Tempest Therapeutics’s complete esg history, request access »

Tempest Therapeutics FAQs

  • When was Tempest Therapeutics founded?

    Tempest Therapeutics was founded in 2011.

  • Where is Tempest Therapeutics headquartered?

    Tempest Therapeutics is headquartered in Brisbane, CA.

  • What is the size of Tempest Therapeutics?

    Tempest Therapeutics has 4 total employees.

  • What industry is Tempest Therapeutics in?

    Tempest Therapeutics’s primary industry is Drug Discovery.

  • Is Tempest Therapeutics a private or public company?

    Tempest Therapeutics is a Public company.

  • What is Tempest Therapeutics’s stock symbol?

    The ticker symbol for Tempest Therapeutics is TPST.

  • What is the current stock price of Tempest Therapeutics?

    As of 20-Nov-2026 the stock price of Tempest Therapeutics is $0.29.

  • What is the current market cap of Tempest Therapeutics?

    The current market capitalization of Tempest Therapeutics is $5.74M.

  • Who are Tempest Therapeutics’s competitors?

    Ayala Pharmaceuticals, Inovio Pharmaceuticals, Aura Biosciences, and AVEO Oncology are competitors of Tempest Therapeutics.

  • What is Tempest Therapeutics’s annual earnings per share (EPS)?

    Tempest Therapeutics’s EPS for 12 months was -$3.16.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process